

What is claimed is:

1. Use of an interleukin-4 receptor (IL-4R) inhibitor in the manufacture of a medicament for treating moderate-to-severe atopic dermatitis (AD) or improving an AD-associated parameter in a patient with moderate-to-severe AD, wherein the patient is ≥ 12 and < 18 years of age, and wherein the patient has moderate-to-severe AD that cannot be adequately controlled with topical AD medications or is a patient for whom topical treatment is medically inadvisable;

wherein the IL-4R inhibitor is an antibody or antigen-binding fragment thereof that binds IL-4R α , wherein the antibody or antigen-binding fragment thereof comprises three HCDRs (HCDR1, HCDR2 and HCDR3) and three LCDRs (LCDR1, LCDR2 and LCDR3), wherein the HCDR1 comprises the amino acid sequence of SEQ ID NO:3, the HCDR2 comprises the amino acid sequence of SEQ ID NO:4, the HCDR3 comprises the amino acid sequence of SEQ ID NO:5, the LCDR1 comprises the amino acid sequence of SEQ ID NO:6, the LCDR2 comprises the amino acid sequence of SEQ ID NO:7, and the LCDR3 comprises the amino acid sequence of SEQ ID NO:8;

wherein for a patient < 60 kg in weight the IL-4R inhibitor is to be administered at (i) an initial dose of about 400 mg of the IL-4R inhibitor followed by one or more secondary doses of about 200 mg of the IL-4R inhibitor, wherein each secondary dose is to be administered two weeks after the immediately preceding dose; or (ii) for a patient ≥ 60 kg in weight the IL-4R inhibitor is to be administered at an initial dose of about 600 mg of the IL-4R inhibitor followed by one or more secondary doses of about 300 mg of the IL-4R inhibitor, wherein each secondary dose is to be administered two weeks after the immediately preceding dose.

2. The use of claim 1, wherein prior to or at the start of treatment the patient has an attribute selected from the group consisting of:

- (i) the patient has a baseline Investigators Global Assessment (IGA) score = 4;
- (ii) the patient has a baseline IGA score ≥ 3 ;
- (iii) the patient has a baseline Eczema Area and Severity (EASI) score ≥ 16 ;
- (iv) the patient has a baseline Pruritus Numerical Rating Scale (NRS) average score ≥ 4 ;
- (v) the patient has $\geq 10\%$ body surface area (BSA) of AD involvement at baseline;
- (vi) the patient has been previously treated with a topical AD medication; and

(vii) the patient has a concomitant disease or disorder selected from the group consisting of food allergy, asthma, seasonal allergy, allergic conjunctivitis, allergic rhinitis, chronic rhinosinusitis, nasal polyps, house dust allergy, hives, and eosinophilic esophagitis.

3. The use of claim 1 or 2, wherein the patient has moderate-to-severe AD that is not adequately controlled with topical AD therapy.
4. The use of claim 1 or 2, wherein the patient is a patient with moderate-to-severe AD for whom topical AD therapy is not advisable.
5. The use of any one of claims 1 – 4, wherein the patient is <60kg in weight; and wherein the IL-4R inhibitor is to be administered at an initial dose of 400 mg followed by one or more secondary doses of 200mg, wherein each secondary dose is to be administered two weeks after the immediately preceding dose.
6. The use of any one of claims 1 – 4, wherein the patient is ≥ 60 kg in weight; and wherein the IL-4R inhibitor is to be administered at an initial dose of 600 mg followed by one or more secondary doses of 300mg, wherein each secondary dose is to be administered two weeks after the immediately preceding dose.
7. The use of any one of claims 1 – 6, wherein the IL-4R inhibitor is to be administered in combination with a second therapeutic agent selected from the group consisting of a topical corticosteroid, a topical calcineurin inhibitor, an anti-histamine, an emollient, an anti-bacterial therapeutic, and a therapeutic agent for obstructive airway disease.
8. The use of claim 7, wherein the IL-4R inhibitor is to be administered in combination with a topical corticosteroid.
9. The use of any one of claims 1 – 8, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 1 and a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 2.

10. The use of any one of claims 1 – 8, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10.
11. The use of any one of claims 1 – 8, wherein the antibody or antigen-binding fragment thereof is dupilumab or a bioequivalent thereof.
12. The use of any one of claims 1 – 11, wherein the IL-4R inhibitor is to be administered subcutaneously.
13. The use of any one of claims 1 – 12, wherein the IL-4R inhibitor is contained in a container selected from the group consisting of a glass vial, a syringe, a pre-filled syringe, an autoinjector and a microinfuser.
14. The use of any one of claims 1 – 13, wherein the IL-4R inhibitor is contained in a pre-filled syringe.
15. The use of claim 14, wherein the prefilled syringe is a single-dose pre-filled syringe.
16. The use of any one of claims 1 – 13, wherein the IL-4R inhibitor is contained in an autoinjector.
17. The use of any one of claims 1 – 16, wherein the IL-4R inhibitor is contained in a volume of 1.15mL.
18. The use of any one of claims 1 – 16, wherein the IL-4R inhibitor is contained in a volume of 2.25mL.
19. The use of claim 16, wherein the autoinjector comprises a pre-filled syringe.